Biodesix Inc (NAS:BDSX)
$ 22.34 -1.11 (-4.73%) Market Cap: 235.71 Mil Enterprise Value: 277.51 Mil PE Ratio: 0 PB Ratio: 25.68 GF Score: 53/100

Biodesix Inc at Barclays Global Healthcare Conference Transcript

Mar 11, 2026 / 04:00PM GMT
Release Date Price: $19.07 (+1.87%)
Luke Sergott
Barclays - Moderator

Good afternoon, everybody. I'm Luke Sergott. I cover life science tools and diagnostics here at Barclays. With me, it's my pleasure to have Robin Cowie, CFO of Biodesix. Thanks again for making it. And sorry for being a little bit late here. We have a little bit break so we can run over.

Questions & Answers

Luke Sergott
Barclays - Moderator

But I guess let's start off, relatively unfamiliar with the business of meeting you guys a couple of times and scaling up. So for those that aren't familiar with, with what you guys do, kind of walk us through just the one-on-one of where the technology, what the platform is and how you're building it and like where you guys are going.

Robin Cowie
Biodesix Inc - Chief Financial Officer, Treasurer, Secretary

Yeah, sure, absolutely. So Biodesix is a diagnostic company. We're dedicated to developing tests to help improve patient lives and outcomes focusing on specific clinical questions. Commercially, we're primarily focused in the area

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot